Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133715) titled 'Predictive Value of ctDNA Methylation Combined with Multi-subtype Circulating Tumor Cell Detection for Recurrence Risk after Neoadjuvant Therapy in Non-small Cell Lung Cancer' on Sept. 30.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Huadong Hospital
Condition:
Stage IIIIIA non-small cell lung cancer after neoadjuvant immunotherapy-containing treatment, R0 surgical resection, and pathological complete response (pCR, ypT0N0).
Intervention:
MRD-negative group:N/A
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-10-01
Target Sample Size: MRD-neg...